Value £3,709,374

Allos

VC Funding

Seed Angel-backed

Healthcare & Biotech Published 12 January 2026

Summary

In a significant market movement during January 2026, Allos was the subject of a vc funding. The transaction achieved a gross valuation of £3,709,374. Leading the round was Oxford Science Enterprises (OSE), Berkeley Skydeck, Habico Invest, the family office of Danish pharmaceutical group Orifarm.

This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.

Lead Investor / Acquirer

Oxford Science Enterprises (OSE)

Lead Investor / Acquirer

Berkeley Skydeck

Lead Investor / Acquirer

Habico Invest

Lead Investor / Acquirer

the family office of Danish pharmaceutical group Orifarm

Advising Broker

Undisclosed Firm

Related Deals in Healthcare & Biotech

Seed prioritised

VC Funding

Ternary Therapeutics

£3,600,000

Mar 2026

VC Funding

NuVision Biotherapies

£4,800,000

Mar 2026

VC Funding

Scan.com

£67,220,000

Sept 2026

VC Funding

Evaro

£18,000,000

Jan 2026

View Company Details

Financials, officers, full deal history

Original Source

This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.

View on Tech.eu Funding Explorer

Funding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.

AI Insight Lenses

Pro

AI-generated analysis from four professional perspectives. Powered by PE Deals.

Free to all registered users.